# Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)

> **NCT02275780** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 769 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** Doravirine
- **DRUG:** Darunavir
- **DRUG:** Ritonavir
- **DRUG:** TRUVADA™ or EPZICOM™/KIVEXA™

## Key facts

- **NCT ID:** NCT02275780
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2016-09-29
- **Final completion:** 2023-03-06
- **Target enrollment:** 769 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275780, "Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02275780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*